aptevotherapeutics.com (APVO) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Aptevo Therapeutics (APVO) is developing scalable platforms for creating anti-tumor antibodies, with primary revenue expected from high-margin licensing royalties. The scientific strategy relies on targeted immuno-oncology and the systematic progression through early clinical trials. This chart shows the market price in the context of EV/EBITDA is 0.00. Business value growth is driven by the success of mipitamonig in treating leukemia, the development of the ADAPTIR system, and partnerships with oncology behemoths.
aptevotherapeutics.com - analytical breakdowns and key metrics (APVO)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Aptevo Therapeutics|APVO - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Aptevo Therapeutics Inc.|APVO - Company Cumulative Debt|Debts to Book Capitalization Aptevo Therapeutics Inc.|APVO - Company Long-Term Debts|Company Short-Term Debt Aptevo Therapeutics|Quick Liquidity Indicator aptevotherapeutics.com
- business earnings and investment ratios data:
APVO - Profit After Payment of Taxes|Projected Future Earnings Aptevo Therapeutics|APVO - Market Cap to Earnings|Projected Price to Earnings Aptevo Therapeutics Inc.|APVO - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc.|APVO - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Aptevo Therapeutics|APVO - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months aptevotherapeutics.com|APVO - Net earnings per one share growth for the current year|Earnings growth forecast for next year Aptevo Therapeutics
Initial company analysis:Aptevo APVO
For Aptevo Therapeutics (APVO), this indicator serves as a tool to compare the total enterprise value, including debt obligations, against its operational efficiency before taxes. By analyzing the EV/EBITDA ratio in a historical context, investors assess the company's ability to generate profit amid the high risk of underfunding clinical trials. This metric's trend helps determine whether the current market capitalization is justified in the face of fierce competition from pharma behemoths.
Competitors of Aptevo Therapeutics
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|DNTH - EV/EBITDA Multiple|Pharvaris N.V. (PHVS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ABCL (AbCellera)|Enterprise Value to EBITDA Ratio TRML|PGEN (Precigen Inc) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PHAR|NKTR - Company Value to EBITDA|Upstream Bio Inc - Enterprise Value to EBITDA Ratio|zenasbio.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Gossamer Bio Inc|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Septerna Pharma - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio PVLA|SVRA (savarapharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RIGL|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXS (Astria Pharma)|enGene Corp (ENGN) - Company Value to EBITDA|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation JBIO (Aerovate Therapeutics Inc)|ACRS: EV/EBITDA Multiple|Kyverna Therapeutics Inc. (KYTX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tiziana Life Sciences PLC|Cabaletta Bio Inc - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple VTYX|THTX - Company Value to EBITDA|Avalo Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Eledon Pharmaceuticals Inc. ELDN|AGEN: Enterprise Value to EBITDA Ratio|Climb Bio, Inc - Enterprise Value to Operating Income Before Depreciation Ratio|ZURA: EV/EBITDA Multiple|ATYR - Total Company Value to Operating Income Before Depreciation Ratio|ADAG (Adagene Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Ikena Oncology, Inc. (IMA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Labs, Inc. (STTK)|Total Company Value to Operating Income Before Depreciation Ratio equilliumbio.com|EV/EBITDA Multiple CNTB (Connect Biopharma Holdings Limited)|EV/EBITDA Multiple Immunic Therapeutics IMUX|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio IFRX|XFOR (X4 Pharma) - Enterprise Value to EBITDA Ratio|ACET (Adicet Bio, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|Company Value to EBITDA inmunebio.com INMB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Barinthus Biotherapeutics plc (BRNS)|KZR: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SABS (SAB Biotherapeutics, Inc)|Business Value to Operating Income Before Depreciation AKTX|Enlivex Therapeutics, Ltd. - EV/EBITDA Multiple|QTTB - EV/EBITDA Multiple|GeoVax (GOVX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Edesa Biotech Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iBio Corp|Enterprise Value to EBITDA Ratio Carisma Tx (CARM)|EV/EBITDA Multiple XTLB|EV/EBITDA Multiple boltbio.com (BOLT)|HCW Biologics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation AIM|Aditxt Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio GRI Bio Corporation GRI|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio reshapelifesciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Revelation Biosciences, Inc.|Enterprise Value to EBITDA Ratio Indaptus Therapeutics Inc (INDP)|Enterprise Value to EBITDA Ratio SCNI (Scinai)|EV/EBITDA Multiple calcimedica.com (CALI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK: Enterprise Value to Operating Income Before Depreciation|HOOKIPA - EV/EBITDA Multiple|Company Value to EBITDA IGM Biosciences, Inc.|ITOS: EV/EBITDA Multiple|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|thirdharmonicbio.com - Company Value to Operating Income Before Depreciation Ratio
